How we spend your money
Money raised by our supporters means The Royal Marsden can continue to provide the best possible treatment and care for patients.
Here’s where we spent that money in 2020 - 2021.
Life-saving research and world-leading treatment and care - £43.4m
Money raised by our supporters means The Royal Marsden can make a vital difference to the lives of cancer patients. With this support the Charity can fund life saving research, enable hospital teams to provide world-leading treatment and care, invest in the latest equipment and fund modern patient environments.
By funding the latest research and equipment, and world-leading professionals, we can ensure that each patient is given the very best treatment and care, supported not just physically, but emotionally and psychologically too.
Our funding also gives cancer patients access to state-of-the-art equipment, enabling new advances in cancer research and care that benefits cancer patients everywhere.
The cancer journey can be uncertain and frightening, and we understand the profound effect a welcoming, dignified environment can have on a patient’s experience – from the moment they are diagnosed through treatment and beyond. Your support ensures cancer patients, their friends and loved ones can have the best possible experience during this time.
Fundraising costs - £5m
These are the direct costs that the Charity incurs in order to raise voluntary income. It costs money to raise money but we continuously look to make savings wherever we can.
Our fundraising activities currently include a £70 million appeal for The Oak Cancer Centre, to be built at The Royal Marsden in Sutton.
This exciting development will be a hub for innovation and discovery - bringing together over 300 clinical researchers alongside our patients in one building, for the first time.
Investment and property management - £0.1m
Our investment portfolio supports the funding of major capital developments and research projects.
At The Royal Marsden Cancer Charity our aim is to maintain the short to medium term value of the portfolio in real terms with a low-to-medium risk portfolio.